FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
FDA General

FDA Opens New, Searchable Adverse Event Platform

FDA launches its new Adverse Event Monitoring System to ultimately house all adverse events reported on FDA-regulated products on one searchable platf...

latest-news-card-1
Human Drugs

FDA OKs Bristol Myers Squibbs Sotyktu for Psoriatic Arthritis

FDA approves Bristol Myers Squibs Sotyktu (deucravacitinib), an oral therapy for treating adults with active psoriatic arthritis.

latest-news-card-1

4 Major Issues Plaguing FDA: Newsweek

A Newsweek report details four major issues it says have plagued FDA in its first year under commissioner Marty Makary.

latest-news-card-1
Biologics

FDA Flags Safety Reporting Lapses at U.K. Clinical Trial Site

FDA cites a U.K.-based clinical research center for failing to promptly report adverse events and for potential falsification of study records during ...

latest-news-card-1
Human Drugs

Vertex Reports Positive Interim Phase 3 Data for Povetacicept

Vertex Pharmaceuticals says an interim analysis of its Phase 3 RAINIER trial showed its experimental therapy povetacicept significantly reduced protei...

latest-news-card-1
Human Drugs

Capricors Duchenne Cell Therapy BLA Resubmitted

FDA accepts for review a Capricor Therapeutics BLA resubmission for its experimental cell therapy deramiocel, intended to treat heart complications in...

latest-news-card-1
Human Drugs

FDA OKs Leucovorin for Ultra-Rare Brain Disorder, But Not Autism

FDA approves an expanded use of GSKs Wellcovorin (leucovorin calcium) tablets for treating cerebral folate deficiency in adult and pediatric patients....

latest-news-card-1
Human Drugs

CGMP Issues at Simtra BioPharma Solutions

FDA warns Westphalia, Germany-based Simtra BioPharma Solutions about CGMP violations in its manufacturing of finished drugs.

latest-news-card-1
Human Drugs

Novo Nordisk PADE Reporting Violations

FDA warns Novo Nordisk in Plainsboro, NJ, about its failure to meet postmarketing adverse drug experience reporting requirements.

latest-news-card-1
Human Drugs

CGMP Violations at Fareva Morton Grove

FDA warns Frances Fareva about CGMP violations in the production of finished drugs at its Morton Grove, IL, manufacturing facility.